SG10201911499TA - Novel anti-angiogenic fusion polypeptides - Google Patents
Novel anti-angiogenic fusion polypeptidesInfo
- Publication number
- SG10201911499TA SG10201911499TA SG10201911499TA SG10201911499TA SG10201911499TA SG 10201911499T A SG10201911499T A SG 10201911499TA SG 10201911499T A SG10201911499T A SG 10201911499TA SG 10201911499T A SG10201911499T A SG 10201911499TA SG 10201911499T A SG10201911499T A SG 10201911499TA
- Authority
- SG
- Singapore
- Prior art keywords
- fusion polypeptides
- novel anti
- angiogenic fusion
- angiogenic
- novel
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/515—Angiogenesic factors; Angiogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2318/00—Antibody mimetics or scaffolds
- C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Vascular Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15197019 | 2015-11-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201911499TA true SG10201911499TA (en) | 2020-01-30 |
Family
ID=54754521
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201803732PA SG11201803732PA (en) | 2015-11-30 | 2016-11-30 | Novel anti-angiogenic fusion polypeptides |
| SG10201911499TA SG10201911499TA (en) | 2015-11-30 | 2016-11-30 | Novel anti-angiogenic fusion polypeptides |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201803732PA SG11201803732PA (en) | 2015-11-30 | 2016-11-30 | Novel anti-angiogenic fusion polypeptides |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US10703810B2 (ru) |
| EP (1) | EP3383921A4 (ru) |
| JP (1) | JP2019505565A (ru) |
| KR (1) | KR20180083943A (ru) |
| CN (1) | CN108699162A (ru) |
| AU (1) | AU2016363668A1 (ru) |
| BR (1) | BR112018010887A2 (ru) |
| CA (1) | CA3004918A1 (ru) |
| EA (1) | EA035586B1 (ru) |
| MX (1) | MX2018006559A (ru) |
| SG (2) | SG11201803732PA (ru) |
| WO (1) | WO2017091850A1 (ru) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2015205530B8 (en) * | 2014-01-13 | 2019-09-19 | Pieris Pharmaceuticals Gmbh | Multi-specific polypeptide useful for localized tumor immunomodulation |
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| IL260323B1 (en) | 2015-12-30 | 2024-09-01 | Kodiak Sciences Inc | Antibodies and their conjugates |
| US12071476B2 (en) | 2018-03-02 | 2024-08-27 | Kodiak Sciences Inc. | IL-6 antibodies and fusion constructs and conjugates thereof |
| CN109829882B (zh) * | 2018-12-18 | 2020-10-27 | 广州比格威医疗科技有限公司 | 一种糖尿病视网膜病变分期预测方法 |
| US11912784B2 (en) | 2019-10-10 | 2024-02-27 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
| WO2022199603A1 (en) * | 2021-03-25 | 2022-09-29 | Nanjing GenScript Biotech Co., Ltd. | Antibody fusion proteins and uses thereof |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2032831T5 (es) | 1986-08-19 | 2001-02-16 | Genentech Inc | Dispositivo y dispersion para suministro intrapulmonar de factores de crecimiento polipeptidos y citoquinas. |
| JPH01215289A (ja) | 1988-02-22 | 1989-08-29 | Toa Nenryo Kogyo Kk | 遺伝子組換えによる正常ヒト血清アルブミンａの製造方法 |
| FR2649991B2 (fr) | 1988-08-05 | 1994-03-04 | Rhone Poulenc Sante | Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces |
| US5728553A (en) | 1992-09-23 | 1998-03-17 | Delta Biotechnology Limited | High purity albumin and method of producing |
| CA2190502A1 (en) | 1994-05-18 | 1995-11-23 | Robert M. Platz | Methods and compositions for the dry powder formulation of interferons |
| DE4417598A1 (de) | 1994-05-19 | 1995-12-14 | Max Planck Gesellschaft | Verwendung des Tetracyclinpromotors zur stringent regulierten Produktion von rekombinanten Proteinen in prokaryontischen Zellen |
| AU5132096A (en) | 1995-01-30 | 1996-08-21 | Terrapin Technologies, Inc. | Glubodies - multiplicities of proteins capable of binding a variety of small molecules |
| US5908621A (en) | 1995-11-02 | 1999-06-01 | Schering Corporation | Polyethylene glycol modified interferon therapy |
| US6620413B1 (en) | 1995-12-27 | 2003-09-16 | Genentech, Inc. | OB protein-polymer chimeras |
| DE19641876B4 (de) | 1996-10-10 | 2011-09-29 | Iba Gmbh | Streptavidinmuteine |
| WO1998016873A1 (fr) | 1996-10-14 | 1998-04-23 | Firm Forsat Ltd. | Procede de preparation de dispersions a base de composants chromogenes |
| DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
| GB9722131D0 (en) | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
| CA2233725A1 (en) | 1998-03-31 | 1999-09-30 | Hemosol Inc. | Hemoglobin-hydroxyethyl starch complexes |
| ATE307597T1 (de) | 1998-06-08 | 2005-11-15 | Hoffmann La Roche | Verwendung von peg-ifn-alpha und ribavirin zur behandlung chronischer hepatitis c |
| US6403564B1 (en) | 1998-10-16 | 2002-06-11 | Schering Corporation | Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection |
| DE19926068C1 (de) | 1999-06-08 | 2001-01-11 | Arne Skerra | Muteine des Bilin-Bindungsproteins |
| US7211395B2 (en) | 2001-03-09 | 2007-05-01 | Dyax Corp. | Serum albumin binding moieties |
| AU2001298053A1 (en) | 2001-09-27 | 2003-04-14 | Pieris Proteolab Ag | Muteins of apolipoprotein D |
| WO2003029462A1 (en) | 2001-09-27 | 2003-04-10 | Pieris Proteolab Ag | Muteins of human neutrophil gelatinase-associated lipocalin and related proteins |
| AU2003275958A1 (en) | 2003-08-25 | 2005-03-10 | Pieris Proteolab Ag | Muteins of tear lipocalin |
| US7691970B2 (en) | 2003-08-25 | 2010-04-06 | Pieris Ag | Muteins of a bilin-binding protein with affinity for a given target |
| JP2007284351A (ja) | 2004-07-27 | 2007-11-01 | Osaka Bioscience Institute | アミロイド蛋白質の凝集を抑制する物質とその作用 |
| EP2899277A1 (en) | 2004-11-26 | 2015-07-29 | Pieris AG | Compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4) |
| WO2006078717A2 (en) * | 2005-01-19 | 2006-07-27 | Beth Israel Deaconess Medical Center | Lipocalin 2 for the treatment, prevention, and management of cancer metastasis, angiogenesis, and fibrosis |
| JP2009509535A (ja) | 2005-09-27 | 2009-03-12 | アムニクス， インコーポレイテッド | タンパク様薬剤およびその使用 |
| EP2235053A1 (en) | 2007-10-19 | 2010-10-06 | Abbott Laboratories | Glycosylated mammalian ngal and use thereof |
| US20110076723A1 (en) * | 2008-05-23 | 2011-03-31 | Samsung Electronics Co., Ltd. | Antibody-peptide fused synergibody |
| JP5711118B2 (ja) | 2008-06-24 | 2015-04-30 | テクニッシュ ウニヴェルジテート ミュンヘン | 所与の標的に対してアフィニティーを有するｈＮＧＡＬおよび類縁タンパク質のムテイン |
| US8268314B2 (en) * | 2008-10-08 | 2012-09-18 | Hoffmann-La Roche Inc. | Bispecific anti-VEGF/anti-ANG-2 antibodies |
| US8133979B2 (en) | 2008-12-16 | 2012-03-13 | Hoffmann-La Roche Inc. | Antibodies against human angiopoietin 2 |
| KR20110134494A (ko) * | 2009-03-27 | 2011-12-14 | 자이모제네틱스, 인코포레이티드 | 항체-수용체 조합물을 포함하는 다중특이적-결합 단백질을 사용하기 위한 조성물 및 방법 |
| DK2510357T3 (en) * | 2009-12-07 | 2016-07-18 | Pieris Ag | MUTEINS OF HUMAN LIPOCALIN 2 (LCN2, HNGAL) WITH AFFINITY FOR A SPECIFIC TARGET |
| AR080794A1 (es) * | 2010-03-26 | 2012-05-09 | Hoffmann La Roche | Anticuerpos bivalentes biespecificos anti- vegf/ anti-ang-2 |
| RU2625011C2 (ru) * | 2010-08-16 | 2017-07-11 | Пиерис АГ | Белки, связывающиеся с гепсидином |
| EP2640740B1 (en) | 2010-11-15 | 2017-03-15 | Pieris Pharmaceuticals GmbH | Muteins of human lipocalin 2 with affinity for glypican-3 (gpc3) |
| RS62509B1 (sr) * | 2012-07-13 | 2021-11-30 | Roche Glycart Ag | Bispecifična anti-vegf/anti-ang-2 antitela i njihova upotreba u lečenju očnih vaskularnih bolesti |
| WO2014076321A1 (en) | 2012-11-19 | 2014-05-22 | Pieris Ag | Novel specific-binding polypeptides and uses thereof |
| BR112015027385A2 (pt) * | 2013-04-29 | 2017-08-29 | Hoffmann La Roche | Anticorpos modificados de ligação ao fcrn humano e métodos de uso |
| AU2015205530B8 (en) * | 2014-01-13 | 2019-09-19 | Pieris Pharmaceuticals Gmbh | Multi-specific polypeptide useful for localized tumor immunomodulation |
| ES2823563T3 (es) * | 2014-05-22 | 2021-05-07 | Pieris Pharmaceuticals Gmbh | Polipéptidos de unión específica novedosos y usos de los mismos |
| JP6839087B2 (ja) * | 2015-01-28 | 2021-03-03 | ピエリス ファーマシューティカルズ ゲーエムベーハー | 血管新生に特異的な新規のタンパク質 |
| AR103477A1 (es) * | 2015-01-28 | 2017-05-10 | Lilly Co Eli | Compuestos de vegfa / ang2 |
| BR112017017530A2 (pt) | 2015-02-18 | 2018-04-17 | Sanofi | proteínas específicas para pioverdina e pioquelina |
| AU2016258952C1 (en) | 2015-05-04 | 2020-12-24 | Pieris Pharmaceuticals Gmbh | Proteins specific for CD137 |
| EP3298029A1 (en) | 2015-05-18 | 2018-03-28 | Pieris Pharmaceuticals GmbH | Muteins of human lipocalin 2 with affinity for glypican-3 (gpc3) |
-
2016
- 2016-11-30 SG SG11201803732PA patent/SG11201803732PA/en unknown
- 2016-11-30 BR BR112018010887A patent/BR112018010887A2/pt not_active Application Discontinuation
- 2016-11-30 MX MX2018006559A patent/MX2018006559A/es unknown
- 2016-11-30 CN CN201680080597.2A patent/CN108699162A/zh active Pending
- 2016-11-30 US US15/777,340 patent/US10703810B2/en not_active Expired - Fee Related
- 2016-11-30 WO PCT/AU2016/051168 patent/WO2017091850A1/en active Application Filing
- 2016-11-30 EP EP16869402.4A patent/EP3383921A4/en not_active Withdrawn
- 2016-11-30 SG SG10201911499TA patent/SG10201911499TA/en unknown
- 2016-11-30 JP JP2018546726A patent/JP2019505565A/ja active Pending
- 2016-11-30 AU AU2016363668A patent/AU2016363668A1/en not_active Abandoned
- 2016-11-30 EA EA201891141A patent/EA035586B1/ru not_active IP Right Cessation
- 2016-11-30 CA CA3004918A patent/CA3004918A1/en not_active Abandoned
- 2016-11-30 KR KR1020187018593A patent/KR20180083943A/ko unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US10703810B2 (en) | 2020-07-07 |
| CA3004918A1 (en) | 2017-06-08 |
| EP3383921A4 (en) | 2019-04-17 |
| MX2018006559A (es) | 2019-06-12 |
| BR112018010887A2 (pt) | 2018-11-21 |
| JP2019505565A (ja) | 2019-02-28 |
| WO2017091850A1 (en) | 2017-06-08 |
| KR20180083943A (ko) | 2018-07-23 |
| EA035586B1 (ru) | 2020-07-10 |
| CN108699162A (zh) | 2018-10-23 |
| EA201891141A1 (ru) | 2018-10-31 |
| EP3383921A1 (en) | 2018-10-10 |
| SG11201803732PA (en) | 2018-06-28 |
| AU2016363668A1 (en) | 2018-05-24 |
| US20180334499A1 (en) | 2018-11-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201802261B (en) | Polypeptides | |
| HK1244019A1 (zh) | 融合蛋白 | |
| HK1249526A1 (zh) | 抗癌融合多肽 | |
| IL255767A (en) | New polypeptides | |
| HK1250041A1 (zh) | 多肽 | |
| GB201509413D0 (en) | Fusion protein | |
| SG11201707426SA (en) | Anti-cancer fusion polypeptide | |
| HK1232136A1 (zh) | 融合蛋白 | |
| SG10201911499TA (en) | Novel anti-angiogenic fusion polypeptides | |
| ZA201704366B (en) | Il-17a-binding polypeptides | |
| HK1250040A1 (zh) | 多肽 | |
| GB201504691D0 (en) | Fusion protein | |
| HK1257937A1 (zh) | 融合蛋白 | |
| GB201602850D0 (en) | Fusion proteins | |
| GB201713537D0 (en) | Fusion Polypeptide | |
| GB201503789D0 (en) | Fusion polypeptide | |
| GB201515245D0 (en) | Novel polypeptides | |
| GB201502166D0 (en) | Bonding polypeptides |